Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea shareholders approve all resolutions proposed by the Board of Directors
at the Ordinary General Meeting of Shareholders
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 29, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
reported that at today's Ordinary General Meeting of Shareholders for the
financial year 2014, shareholders approved all agenda items proposed by the
Board of Directors. At the meeting, 45.3 percent of Basilea's share capital was
represented.
The shareholders approved the annual report, the financial statements and
consolidated financial statements for the business year 2014, and approved the
release of the members of Basilea's Board of Directors and Management Committee.
Shareholders also approved carrying forward the accumulated deficit and re-
elected PricewaterhouseCoopers AG, Basel as Statutory Auditors for the audit of
the stand-alone and consolidated financial statements for the business year
2015.
All current members of Basilea's Board of Directors were re-elected: Dr. Martin
Nicklasson, Domenico Scala, Hans-Beat Gürtler, Prof. Daniel Lew, Dr. Thomas M.
Rinderknecht, Steven D. Skolsky and Dr. Thomas Werner. Dr. Nicklasson was re-
elected as the Chairman of the Board of Directors. The shareholders also re-
elected Dr. Nicklasson, Mr. Skolsky and Dr. Werner as members of the
Compensation Committee. Dr. Caroline Cron was elected as Independent Voting
Rights Representative. The terms of all these individuals last until the end of
the 2016 Ordinary General Meeting of Shareholders.
The shareholders also approved the increase of the conditional share capital.
Finally, the shareholders approved the proposed maximum aggregate amounts for
the compensation of the Board of Director for the period until the 2016 Ordinary
General Meeting, the maximum aggregate amount of fixed compensation for the
Management Committee for the period of 1 July, 2015 to June 30, 2016, and the
maximum aggregate amount of variable compensation for the Management Committee
for the period from January 1, 2015 to December 31, 2015.
In his presentation to the shareholders at the General Meeting, Chief Executive
Officer Ronald Scott highlighted that the key company goals set for 2014 have
been achieved. This included the submission of the European Marketing
Authorization application for isavuconazole in July 2014, the isavuconazole U.S.
submission by Basilea's partner Astellas and the launch of Basilea's antibiotic
Zevtera(®) (ceftobiprole medocaril) in Germany.
First achievements in 2015 include the U.S. FDA approval of isavuconazole for
the treatment of the severe fungal infections invasive aspergillosis and
mucormycosis. Astellas has just launched the drug as CRESEMBA(®)
(isavuconazonium sulfate) in the United States. Basilea recently launched
Zevtera(®)/Mabelio(®) in France, Italy and the U.K. and strengthened its
oncology portfolio by in-licensing panRAF kinase inhibitors for targeted cancer
therapy.
CEO Ronald Scott said: "We are focused on achieving our further significant
milestones in 2015 to bring the company closer to sustainable profitability. The
European regulatory review of our isavuconazole Marketing Authorization
Application is on track and we anticipate a decision in the fourth quarter of
2015. In preparation for a potential launch of isavuconazole in Europe early
2016 we have initiated pre-launch activities such as the preparation of market
access dossiers. We are anticipating topline data from the ACTIVE phase 3 study
with isavuconazole in invasive candidiasis in the second half of 2015. We also
intend to establish Zevtera in key European markets throughout the year and
establish distribution agreements in additional territories."
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment options
in the therapeutic areas of bacterial infections, fungal infections and cancer.
The company uses the integrated research, development and commercial operations
of its subsidiary Basilea Pharmaceutica International Ltd. to develop and
commercialize innovative pharmaceutical products to meet the medical needs of
patients with serious and life-threatening conditions. Basilea Pharmaceutica
Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange
(SIX: BSLN). Additional information can be found at Basilea's website
www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, PhD | Barbara Zink, PhD, MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.
Press release (PDF):
http://hugin.info/134390/R/1916871/685566.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via GlobeNewswire
[HUG#1916871]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Cyprium Mining Signs Exclusive Agreement to Treat Stockpiles from the Historic Potosi Silver Mine in Santa Eulalia, Mexico
Datum: 29.04.2015 - 17:58 Uhr
Sprache: Deutsch
News-ID 389545
Anzahl Zeichen: 7243
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
